NCI Frederick Cancer Research and Development Center (NCI-FCRDC) Building 427, Room 25, P.O. Box B, Frederick, Maryland 21702-1201

A -- CANCER GENOME ANATOMY PROJECT (CGAP) SOL S97-192 DUE 071597 POC Thomas L. Danver, Sr. Contracts Specialist, 301-846-5422, Contracting Officer -- Dennis J. Dougherty, 301-846-1087 The NCI has recently announced the establishment of the Cancer Genome Anatomy Project (CGAP). The overall goal of the Cancer Genome Anatomy Project is to achieve the comprehensive molecular characterization of normal, precancerous, and malignant cells. NCI has chosen breast, prostate, colon, lung, and ovarian tumors and the normal counterparts as the first five (5) targets from which to develop indexed gene sets for the Tumor Gene Index. SAIC Frederick, as the Operations and Technical Support Contractor for the National Cancer Institute (NCI) at the Frederick Cancer Research and Development Center (FCRDC), is soliciting proposals on a full and open competitive basis for the sequencing of 8,000 to 10,000 cDNA clones weekly for a period of one (1) year. Multiple awards are possible and a cost type contract is anticipated. Estimated issuance of RFP NO. S97-192 is mid to late May and responses are due to be received in the contracting office approximately 45 calendar days thereafter. Requests for copiesof the solicitation shall be forwarded to the attention of Thomas L. Danver, Sr. Contracts Specialist, SAIC Frederick, P. O. Box B, Building 244, Frederick, MD 21702. Telephone requests will not be honored. 1) Determine 5' and/or 3' end sequence (as directed by NCI) from 8,000 independent cDNA clones weekly to meet quality control goals set forth below. Total number of sequence reads will not exceed 10,000 per week. Source of the cDNA clones will be provided at the direction of the National Cancer Institute. 2) Perform insert size determinations on the same 8,000 clones within two (2) weeks following completion of each sequencing effort. 3) Submit all of the sequence data that meets quality control guidelines to Genbank at the direction of the NCI. In general, it is expected that sequence for each clone must be submitted within one (1) week of completion, in the format designated by the NCI, unless otherwise directed by the NCI. 4) Quality control guidelines for DNA sequence will include: a) For each sequence read no more than 2% of the bases may be undetermined. If greater than 2% error, the read is considered a failed attempt. To be considered high quality sequence, there should be no more than 2% difference to known high quality sequences or vector sequences. b) The sequence of the cDNA insert must contain a minimum of 150 contiguous bases (unless the cDNA insert itself is less than 150 bases), and the average read length per cDNA is to be approximately 250 bases. c) Poly -A sequences should not be removed prior to submission and will not count towards the 150 base minimum. d) Vector sequences should be removed prior to submission and will not count towards the 150 base minimum. Note that it is anticipated that vector sequences to be read before entering into the cloned insert will range between 25 to 120 nucleotides. It is important to note that the criteria are put forth by the NCI in order to assure that all clones can be categorized as either a) a newly identified human transcript, orb) a previously identified human transcript. Alternate strate- gies to achieve this classification (including ones that might produce shorter sequence reads) will be considered. In this case, it is incumbent on the applicant to provide the scientific justification that the desired categorization of clones will be accomplished with the same degree of success as would be achieved with the NCI quality control guidelines defined above. (0121)

Loren Data Corp. http://www.ld.com (SYN# 0003 19970505\A-0003.SOL)